2024
Impact of Inpatient Percutaneous Coronary Intervention Volume on 30-Day Readmissions After Acute Myocardial Infarction-Cardiogenic Shock
Bansal K, Gupta M, Garg M, Patel N, Truesdell A, Babar Basir M, Rab S, Ahmad T, Kapur N, Desai N, Vallabhajosyula S. Impact of Inpatient Percutaneous Coronary Intervention Volume on 30-Day Readmissions After Acute Myocardial Infarction-Cardiogenic Shock. JACC Heart Failure 2024 PMID: 39243243, DOI: 10.1016/j.jchf.2024.07.014.Peer-Reviewed Original ResearchPercutaneous coronary interventionCardiogenic shockAcute myocardial infarctionAnnual PCI volumesHeart failureAll-causeHigh-volume PCI centersHigh-volume centersAMI-CSNationwide Readmissions DatabaseMedian annual PCI volumesVolume-outcome relationshipAMI-CS admissionsHospital PCI volumePercutaneous coronary intervention volumeVolume centersOrgan dysfunctionPCI centerMultivariable adjustmentHF readmissionSupportive therapyHighest quartilesQ1 hospitalsNoncardiac readmissionComorbidity burdenContemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis
Bansal K, Majmundar V, Young G, Riello R, Faridi K, Ahmad T, Desai N. Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis. JACC Heart Failure 2024, 12: 1791-1793. PMID: 39115517, DOI: 10.1016/j.jchf.2024.07.002.Peer-Reviewed Original ResearchUtilization of Fixed-Dose Combination Treatment for Hypertension in Medicare and Medicaid From 2016 to 2020
Essa M, Ross J, Dhruva S, Desai N, Spatz E, Faridi K. Utilization of Fixed-Dose Combination Treatment for Hypertension in Medicare and Medicaid From 2016 to 2020. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010697. PMID: 38712553, DOI: 10.1161/circoutcomes.123.010697.Peer-Reviewed Original ResearchMedicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications
Young G, Bansal K, Riello R, Clark K, Dhruva S, Faridi K, Desai N. Medicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications. JAMA Network Open 2024, 7: e2412437. PMID: 38771578, PMCID: PMC11109768, DOI: 10.1001/jamanetworkopen.2024.12437.Peer-Reviewed Original ResearchReal-world evaluation of an algorithmic machine-learning-guided testing approach in stable chest pain: a multinational, multicohort study
Oikonomou E, Aminorroaya A, Dhingra L, Partridge C, Velazquez E, Desai N, Krumholz H, Miller E, Khera R. Real-world evaluation of an algorithmic machine-learning-guided testing approach in stable chest pain: a multinational, multicohort study. European Heart Journal - Digital Health 2024, 5: 303-313. PMID: 38774380, PMCID: PMC11104476, DOI: 10.1093/ehjdh/ztae023.Peer-Reviewed Original ResearchRisk of acute myocardial infarctionAssociated with lower oddsHospital health systemCoronary artery diseaseCardiac testingRisk of adverse outcomesUK BiobankHealth systemProvider-drivenLower oddsAssociated with better outcomesAcute myocardial infarctionBlack raceStable chest painFemale sexReal world evaluationDiabetes historyMulticohort studyFunction testsSuspected coronary artery diseaseYounger ageRisk profileAdverse outcomesMultinational cohortPost hoc analysisEpidemiology and risk factors for hyperkalaemia in heart failure
Grobbee D, Filippatos G, Desai N, Coats A, Pinto F, Rosano G, Cleland J, Kammerer J, de Arellano A. Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Failure 2024, 11: 1821-1840. PMID: 38439165, PMCID: PMC11287317, DOI: 10.1002/ehf2.14661.Peer-Reviewed Original ResearchHeart failureObservational studyRisk factorsRenin-angiotensin-aldosterone system inhibitorsSevere renal impairmentElevated serum potassiumImpaired renal functionRisk of hyperkalaemiaIncreased risk of mortalityAdverse cardiovascular eventsClinical epidemiological dataFollow-up lengthChronic kidney diseaseRisk of mortalityIdentified risk factorsMild hyperkalaemiaPotassium bindersRenal impairmentConcomitant medicationsHF therapyDiagnosed HFRenal functionSerum potassiumClinical careClinical outcomesBundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure
Oddleifson D, Holmes D, Alhanti B, Xu X, Heidenreich P, Wadhera R, Allen L, Greene S, Fonarow G, Spatz E, Desai N. Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure. JAMA Cardiology 2024, 9: 222-232. PMID: 38170516, PMCID: PMC10765313, DOI: 10.1001/jamacardio.2023.5009.Peer-Reviewed Original ResearchNon-BPCI hospitalsCause readmission rateReadmission ratesHeart failureSignificant differential changesCare measuresHospital participationBPCI hospitalsHospital mortalityEnzyme inhibitors/angiotensin receptor blockersMortality rateBPCI programAngiotensin receptor neprilysin inhibitorEvidence-based β-blockersGuidelines-Heart Failure registryEnd pointBPCI Model 2Heart failure educationAngiotensin receptor blockersPrimary end pointSecondary end pointsThird of patientsCardiac resynchronization therapyCause mortality ratesHeart failure programImplications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure JACC State-of-the-Art Review
Newman J, O'Meara E, Böhm M, Savarese G, Kelly P, Vardeny O, Allen L, Lancellotti P, Gottlieb S, Samad Z, Morris A, Desai N, Rosano G, Teerlink J, Giraldo C, Lindenfeld J. Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 932-950. PMID: 38418008, DOI: 10.1016/j.jacc.2023.12.033.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyAtrial fibrillationHeart failureAssociated with significant morbiditySpectrum of ejection fractionPrevention of AFIncidence of AFGuideline-directed therapyDiagnosis of AFEjection fractionSignificant morbidityMedical therapyJACC State-of-the-Art ReviewPatientsFrequent hospitalizationsIncreased life expectancyAssociated with greater symptom burdenCardiovascular conditionsGreater symptom burdenTherapySymptom burdenLife expectancyFibrillationHeartPrognosisHeart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape
Desai N, Olewinska E, Famulska A, Remuzat C, Francois C, Folkerts K. Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape. Heart Failure Reviews 2024, 29: 631-662. PMID: 38411769, PMCID: PMC11035416, DOI: 10.1007/s10741-024-10385-y.Peer-Reviewed Original ResearchRandomized controlled trialsHeart failureUnmet medical needAssociated with considerable morbidityDisease burdenPatient outcomesSymptomatic HF patientsEconomic burdenOverview of heart failureComposite cardiovascular deathClinical practice guidelinesGlobal healthcare concernMedical needPoor patient outcomesTargeted literature reviewPreventable disease burdenTreatment landscapeHFmrEF/HFpEFHF hospitalizationHF patientsCardiovascular deathElectronic databasesPatient characteristicsStudy characteristicsMortality riskIntermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins
Vijayaraghavan K, Baum S, Desai N, Voyce S. Intermediate and long-term residual cardiovascular risk in patients with established cardiovascular disease treated with statins. Frontiers In Cardiovascular Medicine 2024, 10: 1308173. PMID: 38288054, PMCID: PMC10822878, DOI: 10.3389/fcvm.2023.1308173.Peer-Reviewed Original ResearchLDL-CCV riskPeripheral arterial diseaseArtery diseaseCumulative incidence of CV eventsCV diseaseLowering of low-density lipoprotein cholesterolPatients treated with statinsIncidence of CV eventsLong-term event ratesWell-controlled LDL-CLow-density lipoprotein cholesterolLDL-C reductionAdd-on agentEvent ratesFirst-line treatmentResidual cardiovascular riskCV event ratesCoronary artery diseaseCV-related deathOmega-3 fatty acids eicosapentaenoic acidFirst-lineCumulative incidenceEicosapentaenoic acidCV eventsApproval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story
Goldsweig A, Deng Y, Yao X, Desai N, Cohen D, Aronow H, Messé S, Ross J, Lansky A, Savitz S. Approval, Evidence, and “Off-Label” Device Utilization: The Patent Foramen Ovale Closure Story. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010200. PMID: 38189127, PMCID: PMC10844981, DOI: 10.1161/circoutcomes.123.010200.Peer-Reviewed Original ResearchStroke/systemic embolismTransient ischemia attackPFO closureSystemic embolismIschemia attackRetrospective cohort studyTransient ischemic attackHalf of patientsOptumLabs Data WarehouseCommercial insurance enrolleesRegulatory approvalClinical trial publicationsIschemic attackRecurrent strokeCohort studyPatent foramenUnderwent closureAtrial fibrillationClinical trialsInsurance enrolleesDecompression illnessTrial publicationsOff labelPatientsProcedure volume
2023
Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction
Fuery M, Leifer E, Samsky M, Sen S, O'Connor C, Fiuzat M, Ezekowitz J, Piña I, Whellan D, Mark D, Felker G, Desai N, Januzzi J, Ahmad T. Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 12: 479-487. PMID: 38127049, DOI: 10.1016/j.jchf.2023.11.007.Peer-Reviewed Original ResearchNT-proBNP measurementsPrimary trial endpointChronic heart failureNT-proBNP levelsReduced ejection fractionTrial endpointsHeart failureEjection fractionN-terminal pro-B-type natriuretic peptide (NT-proBNP) measurementBaseline NT-proBNP levelsChronic heart failure patientsNT-proBNP monitoringSecondary trial endpointsHeart failure hospitalizationNatriuretic peptide measurementHeart failure patientsCardiovascular deathFailure hospitalizationNT-proBNPFailure patientsPrognostic impactClinical outcomesPrognostic valueOutpatient sitesClinical studiesRationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use
Clark K, Victoria-Castro A, Ghazi L, Yamamoto Y, Coronel-Moreno C, Kadhim B, Riello R, O'Connor K, Ahmad T, Wilson F, Desai N. Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use. JACC Heart Failure 2023, 12: 322-332. PMID: 37943221, DOI: 10.1016/j.jchf.2023.08.025.Peer-Reviewed Original ResearchBest practice alertMineralocorticoid receptor antagonistsNovel potassium bindersPotassium bindersEligible patientsUsual careEjection fractionSerum potassiumHistory of hyperkalemiaIncidence of hyperkalemiaStrong guideline recommendationsHeart failure hospitalizationReduced ejection fractionLaboratory test valuesPopulation health outcomesHyperkalemia treatmentMRA prescriptionAntagonist useFailure hospitalizationPatient characteristicsSecondary outcomesHeart failurePrimary outcomeGuideline recommendationsOutpatient visitsImpact of Digital Health Technology on Quality of Life in Patients With Heart Failure
Victoria-Castro A, Martin M, Yamamoto Y, Melchinger H, Weinstein J, Nguyen A, Lee K, Gerber B, Calderon F, Subair L, Lee V, Williams A, Shaw M, Arora T, Garcez A, Desai N, Ahmad T, Wilson F. Impact of Digital Health Technology on Quality of Life in Patients With Heart Failure. JACC Heart Failure 2023, 12: 336-348. PMID: 37943227, DOI: 10.1016/j.jchf.2023.09.022.Peer-Reviewed Original ResearchOverall summary scoreClinical summary scoreTotal symptom scoreKCCQ overall summary scoreUsual careHeart failureQuality of lifeMedian changeKansas City Cardiomyopathy Questionnaire overall summary scoreSummary scoresMedian agePrimary outcomeSymptom scoresPhysical functionLongitudinal carePatientsDigital health toolsLarger studyDigital health technologiesHealth toolsQoLCareDigital interventionsIndependent effectsHealth technologiesACC/AHA Hypertension Guidelines and CHA2DS2-VASc Up-Scoring in Patients With Atrial Fibrillation
Pundi K, Gosch K, Perino A, Jones P, Desai N, Maddox T, Turakhia M. ACC/AHA Hypertension Guidelines and CHA2DS2-VASc Up-Scoring in Patients With Atrial Fibrillation. JAMA Network Open 2023, 6: e2335722. PMID: 37751209, PMCID: PMC10523168, DOI: 10.1001/jamanetworkopen.2023.35722.Peer-Reviewed Original ResearchElectronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial
Ghazi L, Yamamoto Y, Fuery M, O'Connor K, Sen S, Samsky M, Riello R, Dhar R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial. European Heart Journal 2023, 44: 4233-4242. PMID: 37650264, DOI: 10.1093/eurheartj/ehad512.Peer-Reviewed Original ResearchGuideline-directed medical therapyAcute heart failureMineralocorticoid receptor antagonistsHeart failureElectronic health recordsGDMT prescriptionPrimary outcomeEnzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitorsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorElectronic health record alertsEvidence-based regimenProviders of patientsReduced ejection fractionCotransporter 2 inhibitorsRelevant patient characteristicsTime of dischargePre-specified criteriaAHF hospitalizationEligible patientsInpatient initiationPatient characteristicsEjection fractionHospitalized patientsMedian ageClinical Phenotyping with an Outcomes-driven Mixture of Experts for Patient Matching and Risk Estimation
Hurley N, Dhruva S, Desai N, Ross J, Ngufor C, Masoudi F, Krumholz H, Mortazavi B. Clinical Phenotyping with an Outcomes-driven Mixture of Experts for Patient Matching and Risk Estimation. ACM Transactions On Computing For Healthcare 2023, 4: 1-18. PMID: 37908872, PMCID: PMC10613929, DOI: 10.1145/3616021.Peer-Reviewed Original ResearchElectronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure
Fuery M, Kadhim B, Samsky M, Freeman J, Clark K, Desai N, Wilson F, Ahmed T, Ahmad T. Electronic Health Record Embedded Strategies for Improving Care of Patients With Heart Failure. Current Heart Failure Reports 2023, 20: 280-286. PMID: 37552356, DOI: 10.1007/s11897-023-00614-0.Peer-Reviewed Original ResearchConceptsHeart failure patientsFailure patientsElectronic health recordsEHR alertClinical trialsRandomized clinical trialsCare of patientsQuality of careHeart failureClinician satisfactionRandomized fashionRecent FindingsTherePatientsUnmet needPatient careClinical decisionEvidence-based decisionsFuture interventionsCareHealth recordsTrialsCliniciansInterventionFindingsThereHealthcare Market-Level and Hospital-Level Disparities in Access to and Utilization of High-Quality Hip and Knee Replacement Hospitals Among Medicare Beneficiaries
Oddleifson D, Xu X, Wiznia D, Gibson D, Spatz E, Desai N. Healthcare Market-Level and Hospital-Level Disparities in Access to and Utilization of High-Quality Hip and Knee Replacement Hospitals Among Medicare Beneficiaries. Journal Of The American Academy Of Orthopaedic Surgeons 2023, 31: e961-e973. PMID: 37543752, DOI: 10.5435/jaaos-d-23-00183.Peer-Reviewed Original ResearchUtilization of hospitalKnee replacementMedicaid ServicesHospital-level disparitiesLow-income patientsCross-sectional studyHospital-level analysisHospital referral regionsHigh-quality hospitalsReplacement hospitalNational averageCare measuresHospital's percentageReferral regionsMedicare beneficiariesHospitalLevel IIIPatient accessHipSocioeconomic disparitiesSurgical processQuartileLogit linkHigh social vulnerabilityAssociationTranslating Evidence-based Approaches into optimal Care for individuals at High-risk of ASCVD: Pilot testing of case-based e-learning modules and design of the TEACH-ASCVD study
Clegg K, Schubert T, Block R, Burke F, Desai N, Greenfield R, Karalis D, Kris-Etherton P, McNeal C, Nahrwold R, Peña J, Plakogiannis R, Wong N, Jones L. Translating Evidence-based Approaches into optimal Care for individuals at High-risk of ASCVD: Pilot testing of case-based e-learning modules and design of the TEACH-ASCVD study. Journal Of Clinical Lipidology 2023, 17: 592-601. PMID: 37550150, DOI: 10.1016/j.jacl.2023.07.007.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseEvidence-based guidelinesASCVD patientsDetailed patient historyCause of deathClinical best practicesBetter patient careEvidence-based managementU.S. health systemEvidence-based approachOptimal careCardiovascular diseasePatient historyDiagnostic criteriaClinician groupsField of lipidologyPatient careHealth systemCliniciansPatientsCarePilot testingGuidelinesFocus groupsElicit feedback